| 1880 |
Access to New Regimens to Patients Seeking Care in Private/Other Sectors |
02/06/2024 |
DR-TB and PMDT |
| 1907 |
Active TB Drug Safety Monitoring [aDSM] |
02/06/2024 |
DR-TB and PMDT |
| 6341 |
Adult BCG Vaccination- Preparatory Activities |
02/06/2024 |
|
| 6338 |
Adult BCG Vaccination- Study Population: Inclusion Criteria |
02/06/2024 |
|
| 6342 |
Adult BCG Vaccination- Ethical Consideration |
02/06/2024 |
|
| 6343 |
Adult BCG Vaccination- Beneficiary Consent for Adult BCG Vaccination |
02/06/2024 |
|
| 6344 |
Adult BCG Vaccination- Monitoring and Safety Evaluation Plan |
02/06/2024 |
|
| 6345 |
Adult BCG Vaccination- Monitoring and Statistical Analysis Plan for Impact on TB Notification |
02/06/2024 |
|
| 6340 |
Adult BCG Vaccination- Special consideration for Adult BCG vaccination |
02/06/2024 |
|
| 6339 |
Adult BCG Vaccination- Study Population : Exclusion Criteria |
02/06/2024 |
|
| 1909 |
Adverse Event Definitions and Classifications |
02/06/2024 |
DR-TB and PMDT |
| 1997 |
Diagnostic Algorithm for Paediatric DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 2039 |
Use of M/XDR-TB Regimen in Pre-existing liver disease |
02/06/2024 |
DR-TB and PMDT |
| 2616 |
Reporting of Adverse Events and Serious Adverse Events |
02/06/2024 |
DR-TB and PMDT |
| 2618 |
Goals of DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 2620 |
Treatment of DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 2623 |
Role of the District Drug Store [DDS] in the Constitution of Patient-wise Boxes |
02/06/2024 |
DR-TB and PMDT |
| 6325 |
Adult BCG vaccination-Study methodology and objectives |
02/06/2024 |
TB Vaccines |
| 6336 |
Adult BCG Vaccination- Expected Study Outcomes |
02/06/2024 |
TB Vaccines |
| 6337 |
Adult BCG Vaccination-Study settings |
02/06/2024 |
TB Vaccines |
| 2630 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Dosage of Drugs for Adults |
02/06/2024 |
DR-TB and PMDT |
| 2632 |
Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 3202 |
Interim reports of DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 3203 |
DR-TB Counselling Register |
02/06/2024 |
DR-TB and PMDT |
| 3243 |
PMDT Review Mechanisms |
02/06/2024 |
DR-TB and PMDT |
| 3907 |
MTB Drug Resistance |
02/06/2024 |
DR-TB and PMDT |
| 3908 |
Mechanism of action-anti TB drugs first line and second line |
02/06/2024 |
DR-TB and PMDT |
| 4329 |
Presumptive NTM |
02/06/2024 |
DR-TB and PMDT |
| 4330 |
Isolated Non-TB Mycobacteria and their sites of infection |
02/06/2024 |
DR-TB and PMDT |
| 4331 |
Diagnosis of NTM Lung Disease |
02/06/2024 |
DR-TB and PMDT |
